Nanostructured porous Si-based nanoparticles for targeted drug delivery

One of the backbones in nanomedicine is to deliver drugs specifically to unhealthy cells. Drug nanocarriers can cross physiological barriers and access different tissues, which after proper surface biofunctionalization can enhance cell specificity for cancer therapy. Recent developments have highlighted the potential of mesoporous silica (PSiO2) and silicon (PSi) nanoparticles for targeted drug delivery. In this review, we outline and discuss the most recent advances on the applications and developments of cancer therapies by means of PSiO2 and PSi nanomaterials. Bio-engineering and fine tuning of anti-cancer drug vehicles, high flexibility and potential for sophisticated release mechanisms make these nanostructures promising candidates for “smart” cancer therapies. As a result of their physicochemical properties they can be controllably loaded with large amounts of drugs and coupled to homing molecules to facilitate active targeting. The main emphasis of this review will be on the in vitro and in vivo studies.

[1]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[2]  K. Griebenow,et al.  Stimulus-responsive controlled release system by covalent immobilization of an enzyme into mesoporous silica nanoparticles. , 2012, Bioconjugate chemistry.

[3]  Kemin Wang,et al.  In vivo study of biodistribution and urinary excretion of surface-modified silica nanoparticles. , 2008, Analytical chemistry.

[4]  C. Betty.  Porous silicon: a resourceful material for nanotechnology. , 2008, Recent patents on nanotechnology.

[5]  H. Santos,et al.  Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles. , 2011, Biomaterials.

[6]  Qianjun He,et al.  An anticancer drug delivery system based on surfactant-templated mesoporous silica nanoparticles. , 2010, Biomaterials.

[7]  Dong Chen,et al.  The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. , 2010, Biomaterials.

[8]  J. Salonen,et al.  Mesoporous silicon in drug delivery applications. , 2008, Journal of pharmaceutical sciences.

[9]  H. Maeda,et al.  Enhanced Vascular Permeability in Solid Tumor Is Mediated by Nitric Oxide and Inhibited by Both New Nitric Oxide Scavenger and Nitric Oxide Synthase Inhibitor , 1994, Japanese journal of cancer research : Gann.

[10]  Zongxi Li,et al.  Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. , 2010, Small.

[11]  Mark B. Carter,et al.  The Targeted Delivery of Multicomponent Cargos to Cancer Cells via Nanoporous Particle-Supported Lipid Bilayers , 2011, Nature materials.

[12]  Qiuhong Hu,et al.  Adsorption and release of biocides with mesoporous silica nanoparticles. , 2012, Nanoscale.

[13]  Michael J Sailor,et al.  Biodegradable luminescent porous silicon nanoparticles for in vivo applications. , 2009, Nature materials.

[14]  Jia Guo,et al.  Facile synthesis of pH sensitive polymer-coated mesoporous silica nanoparticles and their application in drug delivery. , 2011, International journal of pharmaceutics.

[15]  Vesa-Pekka Lehto,et al.  Fabrication and chemical surface modification of mesoporous silicon for biomedical applications , 2008 .

[16]  Robert Langer,et al.  The biocompatibility of mesoporous silicates. , 2008, Biomaterials.

[17]  Mauro Ferrari,et al.  Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. , 2011, Accounts of chemical research.

[18]  Juan L. Vivero-Escoto,et al.  Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. , 2008, Advanced drug delivery reviews.

[19]  C. Jeffrey Brinker,et al.  Porous nanoparticle supported lipid bilayers (protocells) as delivery vehicles. , 2009, Journal of the American Chemical Society.

[20]  S. Nie,et al.  Nanotechnology applications in cancer. , 2007, Annual review of biomedical engineering.

[21]  Jeremy L. Steinbacher,et al.  Gd-labeled microparticles in MRI: in vivo imaging of microparticles after intraperitoneal injection. , 2010, Small.

[22]  E. Garrone,et al.  Pores occlusion in MCM-41 spheres immersed in SBF and the effect on ibuprofen delivery kinetics: a quantitative model , 2010 .

[23]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[24]  Victor S-Y Lin,et al.  Mesoporous silica nanoparticle based controlled release, drug delivery, and biosensor systems. , 2007, Chemical communications.

[25]  Xu Wang,et al.  Application of Nanotechnology in Cancer Therapy and Imaging , 2008, CA: a cancer journal for clinicians.

[26]  R. J. Lee,et al.  Targeted drug delivery via the folate receptor. , 2000, Advanced drug delivery reviews.

[27]  J. Ho,et al.  Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding. , 2010, ACS nano.

[28]  Hamidreza Ghandehari,et al.  Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. , 2011, ACS nano.

[29]  Mauro Ferrari,et al.  Nanotechnology for breast cancer therapy , 2009, Biomedical microdevices.

[30]  H. Gu,et al.  Synthesis and characterization of pore size-tunable magnetic mesoporous silica nanoparticles. , 2011, Journal of colloid and interface science.

[31]  A. Saboury,et al.  The effect of functionalization of mesoporous silica nanoparticles on the interaction and stability of confined enzyme. , 2012, International journal of biological macromolecules.

[32]  J. Zink,et al.  In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[33]  Dean-Mo Liu,et al.  Magnetic-sensitive silica nanospheres for controlled drug release. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[34]  Cecilia Sahlgren,et al.  Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles--opportunities & challenges. , 2010, Nanoscale.

[35]  Jayanth Panyam,et al.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. , 2010, Biomaterials.

[36]  Tian Xia,et al.  Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. , 2011, ACS nano.

[37]  Brian G Trewyn,et al.  Mesoporous silica nanomaterial-based biotechnological and biomedical delivery systems. , 2007, Nanomedicine.

[38]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[39]  H. Santos,et al.  Mesoporous materials as controlled drug delivery formulations , 2011 .

[40]  Christy L Haynes,et al.  Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. , 2010, Journal of the American Chemical Society.

[41]  K. Rostamizadeh,et al.  Copolymers: efficient carriers for intelligent nanoparticulate drug targeting and gene therapy. , 2012, Macromolecular bioscience.

[42]  Laurence Raehm,et al.  Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. , 2012, International journal of pharmaceutics.

[43]  P. Candeloro,et al.  Water soluble nanoporous nanoparticle for in vivo targeted drug delivery and controlled release in B cells tumor context. , 2010, Nanoscale.

[44]  Rasmus Niemi,et al.  Targeting of porous hybrid silica nanoparticles to cancer cells. , 2009, ACS nano.

[45]  Linlin Li,et al.  Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery , 2012, Advanced materials.

[46]  Dong Chen,et al.  The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. , 2011, ACS nano.

[47]  Min Zhang,et al.  Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. , 2009, Small.

[48]  Warren C W Chan,et al.  Strategies for the intracellular delivery of nanoparticles. , 2011, Chemical Society reviews.

[49]  Ji-Ho Park,et al.  Cooperative nanomaterial system to sensitize, target, and treat tumors , 2009, Proceedings of the National Academy of Sciences.

[50]  Chin-Tu Chen,et al.  Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. , 2010, Biomaterials.

[51]  F. Maxfield,et al.  Endocytic recycling , 2004, Nature Reviews Molecular Cell Biology.

[52]  A. Lavasanifar,et al.  Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. , 2011, Advanced drug delivery reviews.

[53]  P. Liu,et al.  Mesoporous silica nanoparticles end-capped with collagen: redox-responsive nanoreservoirs for targeted drug delivery. , 2011, Angewandte Chemie.

[54]  W. Freeman,et al.  Porous silicon in drug delivery devices and materials. , 2008, Advanced drug delivery reviews.

[55]  Juan L. Vivero-Escoto,et al.  Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. , 2009, Small.

[56]  Cecilia Sahlgren,et al.  Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage. , 2012, Nanomedicine.

[57]  Robert Langer,et al.  Impact of nanotechnology on drug delivery. , 2009, ACS nano.

[58]  J. Martens,et al.  Use of ordered mesoporous silica to enhance the oral bioavailability of ezetimibe in dogs. , 2012, Journal of pharmaceutical sciences.

[59]  H. Dvorak,et al.  Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. , 1988, The American journal of pathology.

[60]  H. Santos,et al.  Multifunctional porous silicon for therapeutic drug delivery and imaging. , 2011, Current drug discovery technologies.

[61]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[62]  F. Tamanoi,et al.  Tailoring the biodegradability of porous silicon nanoparticles. , 2012, Journal of biomedical materials research. Part A.

[63]  H. Santos,et al.  Drug delivery formulations of ordered and nonordered mesoporous silica: comparison of three drug loading methods. , 2011, Journal of pharmaceutical sciences.

[64]  X. Qu,et al.  Near‐Infrared Light‐Triggered, Targeted Drug Delivery to Cancer Cells by Aptamer Gated Nanovehicles , 2012, Advanced materials.

[65]  E. Ruoslahti,et al.  Magnetic luminescent porous silicon microparticles for localized delivery of molecular drug payloads. , 2010, Small.

[66]  H. Santos,et al.  Drug permeation across intestinal epithelial cells using porous silicon nanoparticles. , 2011, Biomaterials.

[67]  Juan L. Vivero-Escoto,et al.  Mesoporous silica nanoparticles for intracellular controlled drug delivery. , 2010, Small.

[68]  Sung‐Jin Kim,et al.  Intracellular protein delivery by hollow mesoporous silica capsules with a large surface hole , 2012, Nanotechnology.

[69]  Bengt Fadeel,et al.  Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. , 2011, Biochimica et biophysica acta.

[70]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[71]  H. Santos,et al.  Nanostructured porous silicon in preclinical imaging: Moving from bench to bedside , 2013 .

[72]  Neetu Singh,et al.  Nanoparticles that communicate in vivo to amplify tumour targeting. , 2011, Nature materials.

[73]  F Levi,et al.  European cancer mortality predictions for the year 2012. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  Taeghwan Hyeon,et al.  Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. , 2010, Journal of the American Chemical Society.

[75]  Biana Godin,et al.  Biocompatibility assessment of Si-based nano- and micro-particles. , 2012, Advanced drug delivery reviews.

[76]  T. Fahmy,et al.  Application of nanotechnologies for improved immune response against infectious diseases in the developing world. , 2010, Advanced drug delivery reviews.

[77]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[78]  Michael J. Sailor,et al.  Chitosan Hydrogel‐Capped Porous SiO2 as a pH Responsive Nano‐Valve for Triggered Release of Insulin , 2009 .

[79]  Debasish Mishra,et al.  Bio-functionalization of magnetite nanoparticles using an aminophosphonic acid coupling agent: new, ultradispersed, iron-oxide folate nanoconjugates for cancer-specific targeting , 2008, Nanotechnology.

[80]  S. Sahoo,et al.  Cancer nanotechnology: application of nanotechnology in cancer therapy. , 2010, Drug discovery today.

[81]  J. Fraser Stoddart,et al.  Mesoporous Silica Nanoparticles in Biomedical Applications , 2012 .

[82]  A. Lavasanifar,et al.  Part I: targeted particles for cancer immunotherapy. , 2011, Current drug delivery.

[83]  Victor S-Y Lin,et al.  Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. , 2011, ACS nano.

[84]  Jennifer S. Park,et al.  Oxidation-triggered release of fluorescent molecules or drugs from mesoporous Si microparticles. , 2008, ACS nano.

[85]  Cecilia Sahlgren,et al.  Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[86]  Yaping Li,et al.  In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. , 2011, Small.

[87]  Haijiao Zhang,et al.  Synthesis of novel mesoporous silica nanoparticles for loading and release of ibuprofen. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[88]  Vesa-Pekka Lehto,et al.  Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. , 2010, ACS nano.

[89]  Victor S-Y Lin,et al.  Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells. , 2006, Journal of the American Chemical Society.

[90]  Cecilia Sahlgren,et al.  Multifunctional mesoporous silica nanoparticles for combined therapeutic, diagnostic and targeted action in cancer treatment. , 2011, Current drug targets.

[91]  H. Santos,et al.  Cellular interactions of surface modified nanoporous silicon particles. , 2012, Nanoscale.

[92]  Chin-Tu Chen,et al.  Near‐Infrared Mesoporous Silica Nanoparticles for Optical Imaging: Characterization and In Vivo Biodistribution , 2009 .

[93]  Sang Cheon Lee,et al.  Controlled release of guest molecules from mesoporous silica particles based on a pH-responsive polypseudorotaxane motif. , 2007, Angewandte Chemie.

[94]  M. Vallet‐Regí.  Nanostructured mesoporous silica matrices in nanomedicine , 2010, Journal of internal medicine.

[95]  H. Santos,et al.  Nanostructured porous silicon materials: potential candidates for improving drug delivery. , 2012, Nanomedicine.

[96]  Q. Ruan,et al.  Dipolar molecules as impellers achieving electric-field-stimulated release. , 2010, Journal of the American Chemical Society.

[97]  Yaping Li,et al.  Intracellular localization and cytotoxicity of spherical mesoporous silica nano- and microparticles. , 2009, Small.

[98]  Chung-Yuan Mou,et al.  Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. , 2009, Small.

[99]  Xinglu Huang,et al.  The promotion of human malignant melanoma growth by mesoporous silica nanoparticles through decreased reactive oxygen species. , 2010, Biomaterials.

[100]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[101]  Y. Yoshioka,et al.  Size-dependent cytotoxic effects of amorphous silica nanoparticles on Langerhans cells. , 2010, Die Pharmazie.

[102]  Chung-Yuan Mou,et al.  Multifunctional Mesoporous Silica Nanoparticles for Intracellular Labeling and Animal Magnetic Resonance Imaging Studies , 2008, Chembiochem : a European journal of chemical biology.

[103]  H. Santos,et al.  Physicochemical stability of high indomethacin payload ordered mesoporous silica MCM-41 and SBA-15 microparticles. , 2011, International journal of pharmaceutics.

[104]  Yuan Yuan,et al.  Effect of size on the cellular endocytosis and controlled release of mesoporous silica nanoparticles for intracellular delivery , 2012, Biomedical microdevices.

[105]  H. Santos,et al.  The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems. , 2012, Biomaterials.

[106]  H. Santos,et al.  Toxicological profile of therapeutic nanodelivery systems. , 2012, Current drug metabolism.

[107]  W. Freeman,et al.  Sustained Release of a Monoclonal Antibody from Electrochemically Prepared Mesoporous Silicon Oxide , 2010, Advanced functional materials.

[108]  Cheuk Y. Tang,et al.  Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. , 2008, Nano letters.

[109]  A. Taylor,et al.  Equivalent pore modeling: vesicles and channels. , 1983, Federation proceedings.

[110]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.

[111]  Meyya Meyyappan,et al.  Nanotechnology: Opportunities and Challenges , 2003 .

[112]  H. Santos,et al.  Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole. , 2011, International journal of pharmaceutics.

[113]  Monty Liong,et al.  Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells , 2007, Nanobiotechnology : the journal at the intersection of nanotechnology, molecular biology, and biomedical sciences.

[114]  Jeremy L. Steinbacher,et al.  Enhanced uptake of porous silica microparticles by bifunctional surface modification with a targeting antibody and a biocompatible polymer. , 2010, ACS applied materials & interfaces.

[115]  T. Asefa,et al.  Mesoporous silica microparticles enhance the cytotoxicity of anticancer platinum drugs. , 2010, ACS nano.

[116]  Wei-Hsuan Chen,et al.  The FASEB Journal express article 10.1096/fj.05-4288fje. Published online October 17, 2005. , 2022 .

[117]  H. Santos,et al.  ¹⁸F-labeled modified porous silicon particles for investigation of drug delivery carrier distribution in vivo with positron emission tomography. , 2011, Molecular pharmaceutics.

[118]  T. Bein,et al.  Biotin-avidin as a protease-responsive cap system for controlled guest release from colloidal mesoporous silica. , 2009, Angewandte Chemie.

[119]  Nicholas J. Panaro,et al.  Nanotechnology-Based Cancer Therapeutics—Promise and Challenge—Lessons Learned Through the NCI Alliance for Nanotechnology in Cancer , 2011, Pharmaceutical Research.

[120]  L. Ruff,et al.  Multivalent Porous Silicon Nanoparticles Enhance the Immune Activation Potency of Agonistic CD40 Antibody , 2012, Advanced materials.

[121]  Taeghwan Hyeon,et al.  Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. , 2008, Angewandte Chemie.

[122]  Yufang Zhu,et al.  Cytosine-phosphodiester-guanine oligodeoxynucleotide (CpG ODN)-capped hollow mesoporous silica particles for enzyme-triggered drug delivery. , 2011, Dalton transactions.

[123]  K. Scanlon.  Cancer gene therapy: challenges and opportunities. , 2004, Anticancer research.

[124]  T. Asefa,et al.  Mesoporosity and functional group dependent endocytosis and cytotoxicity of silica nanomaterials. , 2009, Chemical research in toxicology.

[125]  Taylor Ae,et al.  Equivalent pore modeling: vesicles and channels. , 1983 .

[126]  Jun Liu,et al.  Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. , 2010, Journal of the American Chemical Society.

[127]  Chung-Yuan Mou,et al.  The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. , 2007, Biomaterials.

[128]  María Vallet-Regí,et al.  Mesoporous materials for drug delivery. , 2007, Angewandte Chemie.

[129]  S. Moghimi,et al.  Liposome-mediated triggering of complement cascade. , 2008, Journal of liposome research.

[130]  Khaled Greish,et al.  Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. , 2010, Methods in molecular biology.

[131]  K. Murakami,et al.  Synthesis of thermosensitive polymer/mesoporous silica composite and its temperature dependence of anion exchange property. , 2011, Journal of colloid and interface science.

[132]  K. Martin,et al.  The chemistry of silica and its potential health benefits. , 2007, The journal of nutrition, health & aging.

[133]  Michael J Sailor,et al.  Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. , 2008, Angewandte Chemie.

[134]  Jianlin Shi,et al.  The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses. , 2010, Biomaterials.